米塔扎平治疗老年抑郁症疗效评价

Observation of the Clinical Efficacy and Safety of Mirtazapine on Elder Depression Treatment

目的:评价米塔扎平(米氮平)治疗老年抑郁症的临床疗效和安全性。方法:对年龄60～80岁、符合CCMD-3抑郁症诊断标准、分别接受米氮平和氟西汀治疗的58例抑郁症患者进行为期6周的观察,并应用汉密尔顿抑郁量表(HAMD)和副反应量表(TESS)评估疗效和安全性。结果:经过6周的治疗,米氮平组HAMD总减分率为69.8%,氟西汀组为72.3%,两组比较无显著性差异(P>0.05);两组内HAMD评分治疗前后比较,差异均有显著意义(P<0.05)。米氮平组嗜睡发生率较高,氟西汀组兴奋、激越发生率较高,差异均有显著性(P<0.05)。结论:米氮平治疗老年抑郁症起效快,疗效好,安全性高。

ObjectiveTo assess the clinical efficacy and safety of Mirtazapine in the treatment of elder depression.MethodsThe 58 cases of 60～80 ages met the diagnostic criterion with CCMD-3 were individually administered the Mirtazapine and Fluoxetine therapies for 6 weeks,the efficacy and safety were evaluated in 60th used the HAMD and TESS the drugs.ResultsAfter 6 weeks,treatment the rate of reduced score of Mirtazapine and Fluoxetine were 69.8% and 72.3%,respectively,there was no significant difference(P > 0.05).The total scores after and before the treatment were significantly different between them(P < 0.05).The side effect of Mirtazapine was somnolence,but the Fluoxetine excitation and agitation shown the significant differences(P < 0.05).ConclusionMirtazapine was a rapid effect,good efficacy and high safty agent.